Reuters logo
BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed
November 13, 2017 / 1:48 PM / 11 days ago

BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed

Nov 13 (Reuters) - Global Blood Therapeutics Inc

* Global Blood Therapeutics announces completion of safety review by independent data and safety monitoring board (DSMB) for phase 3 HOPE study in sickle cell disease Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below